For example, FABP7 and FABP5 inhibitors have been reported to ameliorate symptoms of multiple sclerosis in a mouse model [66]; macrophage-specific ablation of FABP4 or FABP5 in mice is protective against atherosclerosis [67]; an FABP3 inhibitor was found to prevent the α-synuclein toxicity that appears to play a role in neurological disorders such as Parkinson’s disease and dementia [68]; and numerous cancers show elevated levels of FABPs, with gene suppression or ablation inhibiting tumor progression [69]. Here, FABP7 is linked to Parkinson disease.